Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation therapy in children.

Milind D Ronghe1, Christina Halsey, Nicholas J Goulden

  • 1Department of Paediatric Haematology-Oncology, Bristol Royal Hospital for Children, Bristol, UK. milind.ronghe@yorkhill.scot.nhs.uk

Paediatric Drugs
|December 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methotrexate Neurological Toxicities: Current State-of-the-Art.

British journal of hospital medicine (London, England : 2005)·2026
Same author

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia.

Pediatric blood & cancer·2026
Same author

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Leukemia·2026
Same author

Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.

Leukemia·2025
Same author

T cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges.

The Journal of clinical investigation·2025
Same author

Canagliflozin synergises with serine restriction mediating anti-leukaemic effects in T-cell acute lymphoblastic leukaemia.

Molecular metabolism·2025

Pediatric thromboembolic disease (TED) treatment is challenging. Low molecular weight heparins (LMWH) offer advantages over unfractionated heparin (UFH) and warfarin due to better pharmacokinetics and convenience in children.

Area of Science:

  • Pediatric Hematology
  • Thrombosis and Hemostasis

Background:

  • Thromboembolic disease (TED) is a significant cause of morbidity and mortality in pediatric patients.
  • Infants under 1 year and adolescent females are particularly vulnerable to TED.
  • Current treatment strategies for pediatric TED are often extrapolated from adult recommendations, despite ontogenic differences in hemostasis.

Purpose of the Study:

  • To evaluate the efficacy and safety of low molecular weight heparins (LMWH) as an alternative to unfractionated heparin (UFH) and warfarin for treating pediatric thromboembolic disease.
  • To highlight the unique challenges and considerations in managing TED in children.

Main Methods:

  • Review of existing data and clinical experience with anticoagulation therapies in pediatric patients.
  • Comparison of unfractionated heparin (UFH) and warfarin with low molecular weight heparins (LMWH).

Related Experiment Videos

Main Results:

  • Low molecular weight heparins (LMWH) demonstrate comparable efficacy and tolerability to unfractionated heparin (UFH) and warfarin.
  • LMWH offer superior pharmacokinetic profiles, requiring less laboratory monitoring and proving more convenient, especially for children with limited venous access.
  • While LMWH may have a higher initial cost, potential savings from reduced hospital stays may offset this expense.

Conclusions:

  • Low molecular weight heparins (LMWH) represent a favorable and convenient alternative for the treatment of thromboembolic disease (TED) in children.
  • The pharmacokinetic advantages of LMWH are particularly beneficial in pediatric populations.
  • Further research may be warranted to optimize LMWH dosing and management strategies in pediatric TED.